GRAIL CEO Sells Over $1.8 Million in Company Stock

Robert Ragusa, the CEO of cancer detection company GRAIL, sold 37,504 shares of the firm's stock.

Mar. 5, 2026 at 10:28am

Got story updates? Submit your updates here. ›

GRAIL, Inc. (NASDAQ:GRAL) CEO Robert Ragusa sold 37,504 shares of the company's stock on Monday, March 2nd. The shares were sold at an average price of $50.17, for a total value of $1,881,575.68. Following the transaction, Ragusa now directly owns 650,525 shares in the company, valued at approximately $32.6 million.

Why it matters

This sale represents a significant decrease in Ragusa's ownership stake in GRAIL, which is a leading biotech company developing early cancer detection tests. Insider transactions like this can provide insight into management's views on the company's prospects and valuation.

The details

Ragusa's sale of over 37,000 GRAIL shares equates to a 5.45% decrease in his direct ownership of the company. GRAIL's stock price has fluctuated significantly over the past year, trading between a 52-week low of $20.44 and a high of $118.84. The company reported a net loss of $15.15 per share for its most recent fiscal year.

  • Ragusa sold the 37,504 shares on Monday, March 2, 2026.

The players

Robert Ragusa

The CEO of GRAIL, Inc., a biotechnology company focused on early cancer detection.

GRAIL, Inc.

A biotech company dedicated to the early detection of cancer through a multi-cancer blood test, leveraging advances in next-generation sequencing, cell-free DNA analysis and machine learning.

Got photos? Submit your photos here. ›

The takeaway

This insider sale by GRAIL's CEO highlights the volatility and uncertainty surrounding the company's stock and the challenges it faces in commercializing its early cancer detection technology. Investors will be closely watching for any further changes in GRAIL's leadership and ownership structure.